$BDTX
Black Diamond Therapeutics Inc

2018 Q4 Form 10-K Financial Statement

#000170154120000009 Filed on March 24, 2020

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $670.0K $710.0K
YoY Change
% of Gross Profit
Research & Development $2.380M $1.630M
YoY Change
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $20.00K
YoY Change
% of Gross Profit
Operating Expenses $3.046M $2.339M $1.914M
YoY Change
Operating Profit -$3.046M -$2.339M -$1.914M
YoY Change
Interest Expense -$10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$10.00K -$20.00K
YoY Change
Pretax Income -$3.070M -$2.360M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$3.066M -$2.360M -$1.913M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$94.06K -$72.30K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.70M
YoY Change
Cash & Equivalents $51.66M
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $51.68M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $134.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.000K
YoY Change
Total Long-Term Assets $142.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $51.68M
Total Long-Term Assets $142.0K
Total Assets $51.83M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $416.0K
YoY Change
Accrued Expenses $452.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.575M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $4.000M
YoY Change
Total Long-Term Liabilities $4.000M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.575M
Total Long-Term Liabilities $4.000M
Total Liabilities $6.598M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$15.71M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.54M
YoY Change
Total Liabilities & Shareholders Equity $51.83M
YoY Change

Cashflow Statement

Concept 2018 Q4 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$3.066M -$2.360M -$1.913M
YoY Change
Depreciation, Depletion And Amortization $10.00K $10.00K $20.00K
YoY Change
Cash From Operating Activities -$2.380M -$1.860M -$4.210M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K -$60.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$10.00K -$10.00K -$60.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 47.32M 4.990M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.380M -1.860M -4.210M
Cash From Investing Activities -10.00K -10.00K -60.00K
Cash From Financing Activities 47.32M 4.990M 0.000
Net Change In Cash 44.93M 3.120M -4.270M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$2.380M -$1.860M -$4.210M
Capital Expenditures -$10.00K -$10.00K -$60.00K
Free Cash Flow -$2.370M -$1.850M -$4.150M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001701541
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-38501
CY2019 dei Entity Registrant Name
EntityRegistrantName
BLACK DIAMOND THERAPEUTICS, INC.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4254660
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
139 Main Street
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2019 dei City Area Code
CityAreaCode
(617)
CY2019 dei Local Phone Number
LocalPhoneNumber
252-0848
CY2019 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001
CY2019 dei Trading Symbol
TradingSymbol
BDTX
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Public Float
EntityPublicFloat
910076402 USD
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35910705 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154666000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51660000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1048000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
155714000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
51684000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
134000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
55000 USD
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 USD
CY2019Q4 us-gaap Deferred Costs
DeferredCosts
2303000 USD
CY2018Q4 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8000 USD
CY2019Q4 us-gaap Assets
Assets
158295000 USD
CY2018Q4 us-gaap Assets
Assets
51826000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1964000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1707000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2899000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
452000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4863000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2575000 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
16000 USD
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4023000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
4879000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
6598000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
64871795 shares
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44867089 shares
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
64839353 shares
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
64839353 shares
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
33668075 shares
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33668075 shares
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
194727000 USD
CY2018Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
65002000 USD
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
200573000 USD
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60770000 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57803522 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2236672 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2236672 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2173684 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2173684 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3812000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
169000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50970000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15712000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-47157000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-15542000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
158295000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51826000 USD
CY2019 bdtx Related Party Transaction Research And Development Expenses From Transactions With Related Party
RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
9966000 USD
CY2018 bdtx Related Party Transaction Research And Development Expenses From Transactions With Related Party
RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
2403000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21753000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6950000 USD
CY2019 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
445000 USD
CY2018 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
325000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7579000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1954000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
29332000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
8904000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-29332000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8904000 USD
CY2019 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
461000 USD
CY2018 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4000 USD
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-6393000 USD
CY2018 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-15000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5926000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35258000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8931000 USD
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.99
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.42
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2075753 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2018623 shares
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35258000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8931000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3643000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
64000 USD
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-6393000 USD
CY2018 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-15000 USD
CY2019 us-gaap Depreciation
Depreciation
47000 USD
CY2018 us-gaap Depreciation
Depreciation
44000 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-38000 USD
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1024000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12000 USD
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
51000 USD
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1454000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
264000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8454000 USD
CY2019 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-1707000 USD
CY2018 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-213000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1791000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
294000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24674000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
76000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76000 USD
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
129499000 USD
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
52312000 USD
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1743000 USD
CY2018 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127756000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52312000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
103061000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43782000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51660000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7878000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154721000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51660000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154666000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51660000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
55000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154721000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51660000 USD
CY2019 bdtx Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
656000 USD
CY2018 bdtx Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
0 USD
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
94000 USD
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12501503 shares
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60770000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-15542000 USD
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12458000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-6675000 USD
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8931000 USD
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33668075 shares
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3643000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35258000 USD
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
64839353 shares
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
200573000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-47157000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8931000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35258000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50970000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15712000 USD
CY2019 us-gaap Use Of Estimates
UseOfEstimates
Use of estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, the valuation of stock-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
55000 USD
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 USD
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
CY2018Q4 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2019Q4 us-gaap Deferred Costs
DeferredCosts
2303000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
8000 USD
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4000000 USD
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
15000 USD
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4023000 USD
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
6393000 USD
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
10400000 USD
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
276000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
234000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
112000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
134000 USD
CY2019 us-gaap Depreciation
Depreciation
47000 USD
CY2018 us-gaap Depreciation
Depreciation
44000 USD
CY2019Q4 bdtx Accrued Contract Research Service Fees Current
AccruedContractResearchServiceFeesCurrent
434000 USD
CY2018Q4 bdtx Accrued Contract Research Service Fees Current
AccruedContractResearchServiceFeesCurrent
0 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1182000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
357000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
984000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
95000 USD
CY2019Q4 bdtx Accrued Legal Fees Current
AccruedLegalFeesCurrent
299000 USD
CY2018Q4 bdtx Accrued Legal Fees Current
AccruedLegalFeesCurrent
0 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2899000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
452000 USD
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
64871795 shares
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
64871795 shares
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
64839353 shares
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
64839353 shares
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
200573000 USD
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
194727000 USD
CY2019Q4 bdtx Convertible Preferred Stock Total Shares Issuable Upon Conversion
ConvertiblePreferredStockTotalSharesIssuableUponConversion
21499770 shares
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44867089 shares
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
33668075 shares
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33668075 shares
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60770000 USD
CY2018Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
65002000 USD
CY2018Q4 bdtx Convertible Preferred Stock Total Shares Issuable Upon Conversion
ConvertiblePreferredStockTotalSharesIssuableUponConversion
11163845 shares
CY2019Q4 bdtx Right To Elect Directors Number Of Directors
RightToElectDirectorsNumberOfDirectors
2 director
CY2019Q4 bdtx Convertible Preferred Stock Conversion Terms Trigger Stock Price
ConvertiblePreferredStockConversionTermsTriggerStockPrice
4.50
CY2019Q4 bdtx Convertible Preferred Stock Conversion Terms Trigger Minimum Gross Proceeds
ConvertiblePreferredStockConversionTermsTriggerMinimumGrossProceeds
75000000 USD
CY2018 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0 USD
CY2019 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0 USD
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57803522 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24027604 shares
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12785541 shares
CY2019 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 USD
CY2018 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 USD
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
47735 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.66
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
121000 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2330739 shares
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.18
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2378474 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.03
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6722000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2378474 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.03
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6722000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
111633 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.98
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
656000 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.82
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
7000 USD
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
319000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3643000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63000 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3.20
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.13
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.016
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2019 bdtx Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.042
CY2018 bdtx Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.016
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.037
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.198
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.298
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9512000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2904000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1014000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
459000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
657000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
280000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
196000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11002000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4020000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10995000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4010000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7000 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
10000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
10000 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6985000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35258000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8931000 USD
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2075753 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2018623 shares
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.99
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.42
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23889001 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11354975 shares
CY2019Q4 bdtx Lessee Operating Lease Area
LesseeOperatingLeaseArea
2357 sqft
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
223000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
228000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
77000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
528000 USD
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
415000 USD
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
36000 USD
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000 USD
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
20000 USD
CY2019Q4 bdtx Prepaid Expense Related Party Current
PrepaidExpenseRelatedPartyCurrent
916000 USD
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1707000 USD
CY2019 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10411000 USD
CY2018 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2728000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6999000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
8148000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.87
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.99
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3841000 USD
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
10344000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
29332000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3841000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6999000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8148000 USD
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10344000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-29332000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3828000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-12287000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-9268000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-9875000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35258000 USD
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.50
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.63
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.99
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1605000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
1914000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
2339000 USD
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
3046000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
8904000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1605000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1914000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2339000 USD
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3046000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8904000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1592000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1913000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-2360000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-3066000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8931000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.51
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.42

Files In Submission

Name View Source Status
0001701541-20-000009-index-headers.html Edgar Link pending
0001701541-20-000009-index.html Edgar Link pending
0001701541-20-000009.txt Edgar Link pending
0001701541-20-000009-xbrl.zip Edgar Link pending
bdtx-20191231.htm Edgar Link pending
bdtx-20191231.xsd Edgar Link pending
bdtx-20191231_cal.xml Edgar Link unprocessable
bdtx-20191231_def.xml Edgar Link unprocessable
bdtx-20191231_g1.jpg Edgar Link pending
bdtx-20191231_g10.jpg Edgar Link pending
bdtx-20191231_g11.jpg Edgar Link pending
bdtx-20191231_g12.jpg Edgar Link pending
bdtx-20191231_g13.jpg Edgar Link pending
bdtx-20191231_g14.jpg Edgar Link pending
bdtx-20191231_g15.jpg Edgar Link pending
bdtx-20191231_g16.jpg Edgar Link pending
bdtx-20191231_g17.jpg Edgar Link pending
bdtx-20191231_g18.jpg Edgar Link pending
bdtx-20191231_g19.jpg Edgar Link pending
bdtx-20191231_g2.jpg Edgar Link pending
bdtx-20191231_g3.jpg Edgar Link pending
bdtx-20191231_g4.jpg Edgar Link pending
bdtx-20191231_g5.jpg Edgar Link pending
bdtx-20191231_g6.jpg Edgar Link pending
bdtx-20191231_g7.jpg Edgar Link pending
bdtx-20191231_g8.jpg Edgar Link pending
bdtx-20191231_g9.jpg Edgar Link pending
bdtx-20191231_htm.xml Edgar Link completed
bdtx-20191231_lab.xml Edgar Link unprocessable
bdtx-20191231_pre.xml Edgar Link unprocessable
exhibit1013.htm Edgar Link pending
exhibit231.htm Edgar Link pending
exhibit311.htm Edgar Link pending
exhibit312.htm Edgar Link pending
exhibit321.htm Edgar Link pending
exhibit44.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending